Sign In
Buy BRCNF
Burcon Nutrascience Earnings Calls
| Release date | Jun 24, 2026 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Expected change | +/- 4.31% |
| Release date | Feb 11, 2026 |
| EPS estimate | - |
| EPS actual | -$0.204 |
| Revenue estimate | 1.5M |
| Revenue actual | 538.209K |
| Revenue Surprise | -64.12% |
| Release date | Nov 12, 2025 |
| EPS estimate | -$0.0400 |
| EPS actual | -$0.210 |
| EPS Surprise | -425.00% |
| Revenue estimate | 1000K |
| Revenue actual | 256.465K |
| Revenue Surprise | -74.35% |
| Release date | Aug 13, 2025 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.200 |
| EPS Surprise | -300.00% |
| Revenue estimate | 900K |
| Revenue actual | 251.163K |
| Revenue Surprise | -72.09% |
Last 4 Quarters for Burcon Nutrascience
Below you can see how BRCNF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 13, 2025 |
| Price on release | $1.99 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.200 |
| EPS surprise | -300.00% |
| Date | Price |
|---|---|
| Aug 07, 2025 | $2.10 |
| Aug 08, 2025 | $2.11 |
| Aug 11, 2025 | $1.99 |
| Aug 12, 2025 | $2.00 |
| Aug 13, 2025 | $1.99 |
| Aug 14, 2025 | $1.99 |
| Aug 15, 2025 | $1.90 |
| Aug 18, 2025 | $1.93 |
| Aug 19, 2025 | $1.95 |
| 4 days before | -5.24% |
| 4 days after | -2.01% |
| On release day | 0% |
| Change in period | -7.14% |
| Release date | Nov 12, 2025 |
| Price on release | $1.70 |
| EPS estimate | -$0.0400 |
| EPS actual | -$0.210 |
| EPS surprise | -425.00% |
| Date | Price |
|---|---|
| Nov 06, 2025 | $1.73 |
| Nov 07, 2025 | $1.72 |
| Nov 10, 2025 | $1.62 |
| Nov 11, 2025 | $1.70 |
| Nov 12, 2025 | $1.70 |
| Nov 13, 2025 | $1.48 |
| Nov 14, 2025 | $1.38 |
| Nov 17, 2025 | $1.40 |
| Nov 18, 2025 | $1.43 |
| 4 days before | -1.73% |
| 4 days after | -16.12% |
| On release day | -12.82% |
| Change in period | -17.57% |
| Release date | Feb 11, 2026 |
| Price on release | $1.33 |
| EPS estimate | - |
| EPS actual | -$0.204 |
| Date | Price |
|---|---|
| Feb 05, 2026 | $1.39 |
| Feb 06, 2026 | $1.42 |
| Feb 09, 2026 | $1.36 |
| Feb 10, 2026 | $1.37 |
| Feb 11, 2026 | $1.33 |
| Feb 12, 2026 | $1.40 |
| Feb 13, 2026 | $1.40 |
| Feb 17, 2026 | $1.36 |
| Feb 18, 2026 | $1.43 |
| 4 days before | -4.32% |
| 4 days after | 7.52% |
| On release day | 5.26% |
| Change in period | 2.88% |
| Release date | Jun 24, 2026 |
| Price on release | - |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Jun 15, 2026 | $1.60 |
| Jun 16, 2026 | $1.60 |
| Jun 17, 2026 | $1.58 |
| Jun 18, 2026 | $1.52 |
| Jun 22, 2026 | $1.60 |
Burcon Nutrascience Earnings Call Transcript Summary of Q4 2025
Burcon reported major execution milestones in the past quarter that materially advance commercialization: closure of a $9.4M rights offering, acquisition of the Galesburg, IL manufacturing facility via an alliance partner (7-year agreement giving Burcon full operational control), first commercial production of its Peazazz C pea protein at that facility, a 20:1 share consolidation, and a $6.8M multi-year contract manufacturing agreement (minimum $1.4M/year). Management emphasized a robust late-stage customer pipeline (many customers evaluating commercial-scale samples), a phased growth plan (Phase 1: producing & selling; Phase 2: scale to Galesburg capacity; Phase 3: broader scaling/licensing), and financial targets: $1–$3M revenue in 2025, $10M+ revenue and cash-flow positivity in calendar 2026. Management expects >50% gross margins at full capacity, believes current cash burn (~$1–$2M/quarter) is sustainable, and highlighted the contract manufacturing deal as an early revenue baseline and operational benefit. Near-term priorities are executing production ramp, converting late-stage customer evaluations to sales, and communicating results to the market.
